Efficacy and safety of cangrelor for patients with coronary artery disease: a meta-analysis of four randomized trials.
Authors:
- 15 January 2015
- journal article
- Vol. 8 (1) , 800-8
Abstract
The efficacy and safety of new intravenous P2Y12 inhibitor (cangrelor) for patients with coronary artery disease (CAD) remain unclear. Trials were identified in PubMed, Web of Science, Embase, and Cochrane Database searches. We included four randomized, placebo-controlled reports in the meta-analysis. The database consisted of 36, 081 patients on cangrelor compared with clopidogrel or placebo. Major adverse cardiac events (MACE) were defined as the primary efficacy endpoint and major or severe bleeding at 48 hours was defined as the primary safety endpoint. Cangrelor significantly decreased risk of MACE (OR: 0.87, P = 0.002) and stent thrombosis (OR: 0.53, P < 0.001). However, at the same time, an increase in TIMI minor bleeding (OR: 1.49, P = 0.04) and in GUSTO moderate bleeding (OR: 1.43, P = 0.04) were observed by cangrelor. Intravenous administration of cangrelor is benefit to reduce risk of MACE and stent thrombosis in patients with CAD excepting for increased minor bleeding events.Keywords
This publication has 27 references indexed in Scilit:
- High-Maintenance-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-AnalysisPLOS ONE, 2013
- Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic EventsNew England Journal of Medicine, 2013
- Effects of Clopidogrel on Vascular Proliferation and Apoptosis in an Atherosclerotic Rabbit ModelJournal of Cardiovascular Pharmacology, 2010
- Intravenous Platelet Blockade with Cangrelor during PCINew England Journal of Medicine, 2009
- Platelet Inhibition with Cangrelor in Patients Undergoing PCINew England Journal of Medicine, 2009
- Aspirin and clopidogrel response variability: review of the published literature.2008
- Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Non–ST-Segment Elevation Acute Coronary SyndromeJACC, 2007
- Clopidogrel Improves Systemic Endothelial Nitric Oxide Bioavailability in Patients With Coronary Artery DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment ElevationNew England Journal of Medicine, 2001
- Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.Circulation, 1987